We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+13.18%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$25B
AUM Growth
+$2.35B
Cap. Flow
+$638M
Cap. Flow %
2.55%
Top 10 Hldgs %
85.68%
Holding
126
New
11
Increased
17
Reduced
63
Closed
6

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$358M
2
PRLD icon
Prelude Therapeutics
PRLD
+$286M
3
KYMR icon
Kymera Therapeutics
KYMR
+$59.8M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$55.5M
5
NRIX icon
Nurix Therapeutics
NRIX
+$45.1M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$94.5M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$26.6M
3
TCDA
Tricida, Inc. Common Stock
TCDA
+$21.6M
4
INSM icon
Insmed
INSM
+$21.6M
5
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$16.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.7%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$9.25B 36.96%
47,269,424
– –
ONC
2
BeOne Medicines Ltd
ONC
$42.4B
$3.81B 15.22%
13,301,597
+1,524,312
+13% +$358M
INCY icon
3
Incyte
INCY
$25.9B
$2.87B 11.47%
31,999,398
+317
+0% +$30.6K
ACAD icon
4
Acadia Pharmaceuticals
ACAD
$5.08B
$1.73B 6.91%
41,904,586
– –
ALXN
5
DELISTED
Alexion Pharmaceuticals
ALXN
$1B 4.01%
8,760,794
– –
KOD icon
6
Kodiak Sciences
KOD
$2.41B
$731M 2.92%
12,352,175
+777,637
+7% +$39M
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$12.9B
$577M 2.31%
7,589,294
– –
ASND icon
8
Ascendis Pharma A/S
ASND
$16.6B
$546M 2.18%
3,540,270
+150,000
+4% +$21.6M
NVTA
9
DELISTED
Invitae Corporation
NVTA
$514M 2.05%
11,850,962
– –
MYOK
10
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$410M 1.64%
3,009,344
-154,890
-5% -$16.5M
PRLD icon
11
Prelude Therapeutics
PRLD
$529M
$305M 1.22%
+10,118,636
New +$286M
ARGX icon
12
argenx
ARGX
$65B
$268M 1.07%
1,019,557
– –
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$234M 0.94%
1,409,784
– –
IGMS
14
DELISTED
IGM Biosciences
IGMS
$232M 0.93%
3,144,446
+223
+0% +$13.2K
EXAS
15
DELISTED
Exact Sciences
EXAS
$188M 0.75%
1,846,139
– –
MDGL icon
16
Madrigal Pharmaceuticals
MDGL
$11.9B
$178M 0.71%
1,499,213
+1
+0% +$109
AMRN
17
Amarin Corp
AMRN
$298M
$135M 0.54%
1,600,943
-123,891
-7% -$14.8M
HRTX icon
18
Heron Therapeutics
HRTX
$60.4M
$88.8M 0.36%
5,994,704
-23,400
-0.4% -$365K
FMTX
19
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$88.3M 0.35%
1,771,509
-228,491
-11% -$9.23M
CERS icon
20
Cerus
CERS
$566M
$85.8M 0.34%
13,713,195
– –
ZYME icon
21
Zymeworks
ZYME
$2.05B
$79.6M 0.32%
1,708,472
– –
INSM icon
22
Insmed
INSM
$27.5B
$73M 0.29%
2,272,712
-752,672
-25% -$21.6M
AXSM icon
23
Axsome Therapeutics
AXSM
$10.9B
$68.4M 0.27%
959,757
-50,000
-5% -$3.9M
NBIX icon
24
Neurocrine Biosciences
NBIX
$15.5B
$65.1M 0.26%
676,975
-230,011
-25% -$26.6M
KYMR icon
25
Kymera Therapeutics
KYMR
$9.96B
$63.3M 0.25%
+1,959,211
New +$59.8M
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2020 Portfolio in Review

As of Q3 2020, Julian Baker held 126 positions worth $25B, up 10% from $22.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q3 2020 filing shows 11 new, 17 increased, 63 reduced and 6 closed positions. Its largest new stake was Prelude Therapeutics: 10,118,636 shares worth $305M. The largest sale was Principia Biopharma Inc. Common Stock, an estimated $94.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q3 2020 buy was Prelude Therapeutics: 10,118,636 shares worth $305M.
  • Julian Baker added most to BeOne Medicines Ltd in Q3 2020, an estimated $358M increase.
  • Julian Baker's biggest Q3 2020 reduction was Neurocrine Biosciences, cutting an estimated $26.6M.
  • Julian Baker fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $94.5M.
  • Julian Baker's ten largest holdings make up 86% of its $25B portfolio in Q3 2020.
  • Julian Baker opened 11 new positions and closed 6 in Q3 2020.
  • Julian Baker's portfolio value rose 10% quarter-over-quarter to $25B.

Based on Baker Bros. Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.